Eloxx Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, Baker Tilly, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9 USD | -1.76% | +5.26% | -25.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.00% | 30.24L | |
+5.66% | 11TCr | |
+11.23% | 11TCr | |
-0.38% | 2.23TCr | |
-12.15% | 2.21TCr | |
-7.66% | 1.87TCr | |
-36.52% | 1.76TCr | |
-10.09% | 1.69TCr | |
+3.33% | 1.38TCr | |
+36.58% | 1.25TCr |
- Stock Market
- Equities
- ELOX Stock
- News Eloxx Pharmaceuticals, Inc.
- Eloxx Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt